Forte Biosciences, Inc. (FBRX) Balance Sheet

The downward trajectory in equity highlights the company's reliance on external financing to offset persistent operating losses. Investors should monitor whether the current capital base can sustain the necessary clinical trial milestones without necessitating further dilutive equity raises in the near term.

The significant reduction in liquidity metrics suggests that the company is consuming its cash reserves at an accelerating pace to fund R&D activities. This trend warrants close scrutiny, as the current liquidity profile provides a finite window for achieving clinical data readouts before the company faces potential funding constraints.

The persistent growth of the accumulated deficit underscores the high-risk nature of the business model, where value is entirely dependent on future clinical success rather than current earnings. This structural deficit implies that any equity value is highly sensitive to the outcome of the FB-102 program, with little support from historical profitability.